OKN-007 is an Effective Anticancer Therapeutic Agent Targeting Inflammatory and Immune Metabolism Pathways in Endometrial Cancer.
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1123243 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Advanced-stage endometrial cancer patients typically receive a combination of platinum and paclitaxel chemotherapy. However, limited treatment options are available for those with recurrent disease, and there is a need to identify alternative treatment options for the advanced setting. Our goal was to evaluate the pre-clinical efficacy and mechanism of action of the anti-cancer drug Oklahoma Nitrone 007 (OKN-007) alone and in combination with carboplatin and paclitaxel in endometrial cancer. The effect of OKN-007 on the metabolic viability of endometrial cancer cells in both two- and three-dimensional (2D and 3D) cultures, as well as on clonogenic growth, in vitro was assessed. We also evaluated OKN-007 in vivo using an intraperitoneal xenograft model and targeted gene expression profiling to determine the molecular mechanism and gene expression programs altered by OKN-007. Our results showed that endometrial cancer cells were generally sensitive to OKN-007 in both 2D and 3D cultures. OKN-007 displayed a reduction in 3D spheroid and clonogenic growth. Subsequent targeted gene expression profiling revealed that OKN-007 significantly downregulated the immunosuppressive immunometabolic regulatory enzyme indolamine 2,3-dioxygenase 1 (IDO1) (-11.27-fold change) and modulated upstream inflammatory pathways that regulate IDO1 expression (interferon- (IFN-), Jak-STAT, TGF-β, and NF-kB), downstream IDO1 effector pathways (mTOR and aryl hydrocarbon receptor (AhR)) and altered T-cell co-signaling pathways. OKN-007 treatment reduced IDO1, SULF2, and TGF-β protein expression in vivo, and inhibited TGF-β, NF-kB, and AhR- receptor-mediated nuclear signaling in vitro. These findings indicate that OKN-007 surmounts pro-inflammatory, immunosuppressive, and pro-tumorigenic pathways and is a promising approach for the effective treat endometrial cancer. Targeted mRNA expression profiling was performed using the nCounter ® Tumor Signaling 360™ Panel (NanoString Technologies), which comprises 780 genes involved in cancer-related pathways and internal reference genes. Raw data were normalized and log2 transformed using the geNorm algorithm, differential expression (DE) was determined using the Generalized Linear Model (GLM), and Gene Set Analysis (GSA) was used to summarize the directed global significance score by calculating the change in regulation within each defined gene set relative to the baseline. Pathway enrichment was also calculated for gene sets as defined in multiple databases, including WikiPathways, REACTOME, MSigDB, and Gene Ontology, and FDR adjustment and p-Elim pruning scores were calculated when appropriate. DE, GSA, and other pathway enrichment were conducted using ROSALIND software (v. 3.38.5.1). Genes with >1.5-or <1.5-fold change at P < 0.05 were considered significantly differentially expressed.
2025-08-01 | GSE269693 | GEO
Project description:We report the effect of Rpx on human PDAC Suit2-007 cells after 48h time point
2020-09-01 | GSE152304 | GEO
Project description:RNA sequencing technology has been carried out in order to compare mRNA expression changes in epithelial BxPC-3 versus mesenchymal S2-007 cells.
2018-04-18 | GSE113259 | GEO
Project description:A heterodimer of α and β hemoglobin chains functions as an innate anticancer agent
| PRJNA935740 | ENA
Project description:Our study investigated the therapeutic potential of OKN-007 in the SOD1 G93A mouse model of amyotrophic lateral sclerosis (ALS). The impact of OKN-007, known for its antioxidant, anti-inflammatory, and neuroprotective properties, was tested at two doses (150 mg/kg and 300 mg/kg) at onset and late-stage disease. Results demonstrated a significant delay in disease progression at both doses, with treated mice showing a slower advance to severe disease stages compared to untreated controls. Transcriptomic analysis using bulk RNA sequencing identified dysregulated genes in G93A mice that were restored by OKN-007 treatment and pathways that showed altered expression in response to OKN-007. Overall, our findings suggest that OKN-007 holds potential as a disease-modifying treatment for ALS, although further research is needed to optimize dosing regimens and understand its long-term effects.
2024-11-10 | GSE281064 | GEO
Project description:The efficacy of killing human cancer cells by a modified Herpes-simplex-virus thymidine kinase TK.007/ganciclovir (GCV) system was investigated in malignant cells of different histogenetic origin. The aim was to determine whether different histogenetic origins of cancer cells in them-selves influence their reaction towards an approach of synthetic lethality, which theoretically should be applicable independently of the cell type. Fifteen malignant human cell lines were transduced with a lentiviral vector to stably express the TK.007 gene and cell proliferation assays under GCV were performed. Among TK.007-expressing cell lines, lymphoma and leuke-mia cells were more susceptible to killing than solid cancer cells, while osteosarcoma and mela-noma cells exhibited an intermediate susceptibility. Similar differences in killing were also noted in wild-type non-transduced cells. This study highlights that the histogenetic origin of malignant cells strongly influences their susceptibility towards cytotoxic agents, with leukemias and lym-phomas being more sensitive than solid cancer cells.
2025-01-17 | PXD052713 | Pride
Project description:Transcriptional profiling was conducted on RNA from 16 prostatic cancer cell lines to identify genes whose expression level correlate with sensitivity of an anti-tumor agent (dasatinib). Keywords: comparison of sensitive group versus resistant group of cell lines to agent
2007-12-01 | GSE9633 | GEO
Project description:Endometrial cancer (EC) is the sixth most prevalent female cancer globally and although high rates of success are achieved when diagnosed at an early stage, the 5-year survival rate for cancers diagnosed at Stages II-IV is below 50%. Improving patient outcomes will necessitate the introduction of novel therapies to the clinic. Pan-cyclin-dependent kinase inhibitors (CDKis) have been explored as therapies for a range of cancers due to their ability to simultaneously target multiple key cellular processes, such as cell cycle progression, transcription, and DNA repair. Few studies, however, have reported on their potential for the treatment of EC. Herein, we examined the effects of the pan-CDKi dinaciclib in primary cells isolated directly from tumors and EC cell lines. Dinaciclib was shown to elicit a bimodal action in EC cell lines, disrupting both cell cycle progression and phosphorylation of the RNA polymerase carboxy terminal domain, with a concomitant reduction in Bcl-2 expression. Furthermore, the therapeutic potential of combining dinaciclib and cisplatin was explored, with the drugs demonstrating synergy at specific doses in Type I and Type II EC cell lines. Together, these results highlight the potential of dinaciclib for use as an effective EC therapy.
| S-EPMC7962054 | biostudies-literature
Project description:Elizabethkingia anophelis FMS-007 Genome sequencing
| PRJNA210135 | ENA